The GFAP-HREN and SYN-HREN constructs were generated as described below. Expression was examined by RNase protection assay in brain (B) and kidney (K) from two different lines of mice for each construct. β -actin was used as an internal control. The HREN probe is entirely internal to the HREN cDNA. The position of HRENspecific band is indicated. +, positive control; -, negative control. Generation of the transgenes: The RhR1100FM cDNA encoding HREN was modified by PCR to contain Xho I and Mlu I ends. The modified RhR1100FM was then cloned into the Xho I-Mlu I sites of pSTEC-1. The human glial fibrillary acidic protein (GFAP) promoter was digested from the plasmid pGfa2Lac-1 with Eco RI and cloned into the Eco RI site of pBluescript ® II SK +/-(Stratagene, La Jolla, CA, USA) to create the plasmid pBS-GFAP. The intron, RhR1100FM, and SV40 polyA were removed from pSTEC-1 and ligated to pBS-GFAP to create GFAP-HREN. The rat synapsin I promoter was amplified from pBL4.3 Syn-CAT to contain Eco RV and BamHI ends. The resultant PCR product was then cloned into the Eco RV-BamHI sites of pBluescript II SK +/to create pBS-SynI. The intron, RhR1100FM, and SV40 polyA were removed from pSTEC-1 to create Syn-HREN. Transgenic mice were generated from a 4.4-kb Bss HII fragment of pG-FAP-HREN and a 6.3-kb Cla I fragment of pSynI-HREN.
The use of transgenic mice has become an important tool for creating novel models of disease by expressing target genes in a tissue-or cell typespecific fashion. One highly successful approach for generating transgenic mice has been to use a genomic clone containing the gene of interest. In these genomic clones, the gene is under the control of its own endogenous promoter, so that it is expressed in an appropriate tissue-specific and regulated fashion, and contains introns, exons, and a polyadenylation (polyA) addition site, resulting in efficient transcription, processing, and transport of the resultant mRNA. Although highly reliable, the use of genomic clones is not always feasible because of either size limitations or the need for an experimental strategy whereby a protein is targeted to a specific cell type. In situations like this, the use of a cDNA encoding the gene of interest fused behind a promoter/enhancer with a known cellular expression profile may prove more desirable and convenient.
Previous studies have indicated that transgenes consisting of cDNAs are expressed at a much higher level when a spliceable intron is included in the construct (2, 3) . Indeed, introns are thought to be required for the proper and efficient maturation of mammalian mR -NAs. Numerous constructs have been successfully employed that contain a 3 ′ cassette consisting of a spliceable intron immediately upstream of a polyA addition site. Transgenes generated in this way have large first exons (consisting of the cDNA) and small terminal exons. However, an analysis of the structure of many genes indicates that most mammalian genes contain small first exons and large terminal exons. We therefore considered that placing a spliceable intron between a promoter and cDNA would result in a transgene construct that may look and function more like a bona fide normal mammalian gene and thus be expressed more reliably. Several plasmid vectors are commercially available in which cDNAs can be placed behind an intron and used in vitro for transient transfection analysis. However, since many of these vectors contain a strong viral promoter to drive expression of the construct, they are not good candidates for use in the generation of transgenic mice when a restricted tissue-specific pattern of expression is desired.
Therefore, we developed two cloning vectors allowing an investigator to: ( i ) easily insert a promoter/enhancer sequence designed to specifically target expression of the desired protein in a tissue-or cell type-specific fashion upstream of a cDNA; ( ii ) easily insert a cDNA encoding the protein of interest downstream of a cell-specific promoter and spliceable intron, and upstream of a polyA addition site; and ( iii ) easily excise the transgene from the prokaryotic vector. Each of these features was considered in the design pSTEC-1 and pSTEC-2, which differ only in the available restriction enzyme sites (Figure 1 ). Specifically, both plasmids contain unique restriction enzyme sites for the insertion of a promoter/enhancer.
Although any combination of the sites can be used, it is important to recognize that one of these unique sites must remain intact to excise the transgene from the plasmid backbone before injection of the fertilized eggs. Each plasmid also contains a chimeric intron composed of the 5 ′ splice site from the β -globin intron and the 3 ′ splice site from an IgG intron. A short 30-bp DNA sequence pSTEC-1, then the Sma I, Kpn I, and Eco RI sites at the 3 ′ end of the plasmid become unique restriction sites. As an alternative to cloning both a promoter and a cDNA into these vectors, once a cDNA has been inserted, the intron-cDNA-polyA segment can be excised and placed downstream of a promoter in a separate plasmid, resulting in an essentially identical construct design.
There are several considerations that should be taken into account when designing promoter fragments and cDNA sequences to be inserted into the pStec vectors. First, the promoter must contain an intact transcription start site to drive transcription of the mRNA of interest. Second, the inserted cDNA must encode its own AUG translation initiation codon. This sequence can either be the native AUG normally present in the gene or optimized to match the Kozak consensus sequence. Finally, it is unnecessary for the cDNA to encode a polyA addition site as one is already contained within the vectors.
To directly test the efficacy of these plasmids, a cDNA encoding the human renin (HREN) gene was first cloned into the cDNA-insertion polylinker, and then the intron-HREN cDNA-polyA segment was cloned downstream of the Synapsin-1 promoter (4) to form the Syn-HREN construct, or the GFAP promoter (1) to form the construct GFAP-hREN. Transgenic mice were generated as previously reported (6) . Transgenic founders and offspring were initially genotyped by PCR using primers specific to the HREN cDNA and later confirmed by Southern blot analysis (5) . HREN and mouse β -actin mRNA levels were determined with an RNase protection assay utilizing a RPA III kit (Ambion, Austin, TX, USA) as previously described (6) .
We tested HREN expression in two lines each of GFAP-HREN and Syn-HREN transgenic mice. High-level HREN mRNA was specifically detected in the brain but not in the kidney of GFAP-HREN or Syn-HREN transgenic mice (Figure 2) , demonstrating the ability of the promoters to direct specific expression of the HREN cDNA. HREN protein was detected by immunohistochemistry, specifically in neurons of the brain of Syn-HREN mice and in glia in the brain of GFAP-HREN mice (unpublished observation).
In summary, we have created two general cloning vectors that allow for specific promoter sequences and cD -NAs to be inserted flanking an intron. The presence of an intron upstream of the cDNA and downstream of the transcription start site may have advantages over designs placing the intron (often as an intron/polyA cassette) downstream of the cDNA as many mammalian genes have very short first exons and longer terminal exons. Each vector has several unique restriction enzyme sites to facilitate the addition of both specific promoter sequences and cDNAs. These vectors could allow for a series of cDNAs to be placed behind a specific promoter or a series of promoters to drive expression of a specific cDNA to different cell types or tissues in transgenic mice.
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